Syndax Pharmaceuticals (SNDX) halted IPF development for axatilimab after its MAXPIRe Phase 2 trial missed the primary endpoint of slowing lung function decline. The stock fell 7.2 percent on the news. Critically, axatilimab showed a safety profile comparable to placebo, eliminating safety concerns as an explanation for the failure.
The IPF miss narrows axatilimab's addressable market but does not impair the approved Niktimvo (axatilimab-csfr) franchise for chronic graft-versus-host disease or the company's oncology pipeline. Syndax confirmed ongoing trials for axatilimab in other indications remain unaffected.
Syndax's 2029 thesis now hinges on Niktimvo and Revuforj. The company projects $748 million in revenue and $110.2 million in earnings by 2029—requiring 63.1 percent annual revenue growth to offset roughly $400 million in annual R&D and SG&A spending. Current consensus estimates are more cautious, projecting $604.5 million in revenue and $104 million in earnings.
The real risk: if Niktimvo's chronic GVHD franchise and frontline trials do not accelerate meaningfully, Syndax will struggle to absorb its cost structure. The IPF failure removes meaningful upside optionality but does not alter near-term catalysts. Investors should focus on Niktimvo uptake and label-expansion data as the primary indicators of whether 2029 targets are achievable.
